Low-Dose Atropine Drops for Myopia Control
Understanding Low-Dose Atropine for Myopia
Myopia, commonly known as nearsightedness, is one of the most prevalent vision conditions in children, and its rates continue to rise worldwide. Low-dose atropine eye drops have emerged as one of the most studied pharmacological treatments for slowing myopia progression in growing eyes. At Greenwich Ophthalmology Associates, our myopia management specialists work with families across the greater NY/CT region to determine whether atropine therapy may help protect your child's long-term vision.
Understanding how these drops work, what to expect during treatment, and how they compare to other options can help you make an informed decision about your child's eye care. The Phase III CHAMP clinical trial, one of the first large-scale studies of low-dose atropine in U.S. and European children, found that a preservative-free formulation of low-dose atropine slowed myopia progression, with the proportion of children showing less than 0.75 diopters of progression reaching approximately 43 percent compared to 29 percent on placebo over three years (Zadnik et al., JAMA Ophthalmology, 2023).
How Low-Dose Atropine Slows Myopia Progression
Low-dose atropine targets the underlying biological mechanisms that drive myopia progression during childhood. Atropine is a muscarinic receptor antagonist, meaning it blocks certain chemical receptors in the eye. In higher concentrations, atropine has long been used to dilate the pupil and temporarily relax the focusing muscle inside the eye. At low doses, however, atropine appears to interact with receptors in the sclera (the white outer wall of the eye) and the retina, influencing signals that control eye growth. Children with myopia experience excessive elongation of the eyeball over time, and atropine may help slow this elongation process.
Every additional millimeter of axial length increases the degree of nearsightedness and raises the risk of sight-threatening complications later in life. Children who develop high myopia face greater chances of retinal detachment, myopic macular degeneration, glaucoma, and early cataracts. By slowing the rate at which the eye elongates during the critical growth years, low-dose atropine can help reduce the total amount of myopia a child accumulates by adulthood.
Low-dose atropine is typically instilled as one drop in each eye at bedtime. Nighttime dosing helps minimize any mild light sensitivity or near-vision effects during the day. The drops are administered daily, and parents can quickly incorporate this step into a child's bedtime routine. Our myopia management specialists demonstrate proper instillation technique and provide guidance to help make the process comfortable for younger children.
Atropine Concentrations Used for Myopia Control
Not all low-dose atropine formulations are the same. Research has evaluated a range of concentrations, and the optimal dose balances effectiveness against side effects. The most widely studied concentrations for myopia control in children include 0.01%, 0.02%, and 0.05% atropine. These are significantly diluted compared to the 0.5% to 1.0% concentrations traditionally used for diagnostic pupil dilation. Each concentration offers a different balance between myopia-slowing effect and visual side effects.
The ATOM2 trial, one of the earliest landmark studies, established 0.01% atropine as a viable option with minimal side effects. The more recent LAMP study found that 0.05% atropine provided stronger myopia control while still maintaining an acceptable side effect profile, emerging as a preferred concentration for many clinicians. Some subsequent studies, including the CHAMP trial, have shown that 0.01% atropine may offer limited benefit over placebo in certain populations. This evolving evidence has led many practitioners to consider 0.05% as an optimal starting concentration, though the choice depends on individual patient factors.
We take several factors into account when recommending a specific concentration, including your child's age, rate of myopia progression, current prescription, and tolerance of the drops. Some children may start at one concentration and adjust over time based on their response. Because these drops are prepared at specialized compounding pharmacies, the concentration can be tailored to each patient's needs.
How Effective Is Atropine at Slowing Myopia
The effectiveness of low-dose atropine has been evaluated in multiple large clinical trials spanning different populations and study designs. Results vary by concentration and patient characteristics, but overall the evidence supports meaningful benefits for many children. Studies have shown that low-dose atropine can slow myopia progression by approximately 30 to 60 percent, depending on the concentration used and the duration of treatment. The LAMP study demonstrated that 0.05% atropine reduced the cumulative incidence of myopia by roughly 25 percent in premyopic children over two years, and showed even stronger effects on slowing prescription changes and axial elongation in already-myopic children.
Effectiveness is assessed through regular monitoring of two key measurements: the refractive error (the glasses prescription) and axial length (the physical length of the eyeball). Axial length measurement using optical biometry is particularly valuable because it provides an objective marker of eye growth independent of focusing fluctuations. We track these measurements at regular intervals, typically every four to six months, to determine whether the treatment is producing the desired response.
Low-dose atropine does not stop myopia progression entirely or reverse existing nearsightedness. The goal is to slow the rate of progression so that your child reaches adulthood with a lower final prescription and reduced risk of high-myopia complications. Understanding realistic expectations for myopia control helps families appreciate the long-term value of treatment even when some progression continues.
Side Effects of Low-Dose Atropine
One of the main advantages of low-dose atropine compared to higher-concentration formulations is its favorable side effect profile. Photophobia, or increased sensitivity to bright light, is the most commonly reported side effect, occurring in roughly 25 percent of children in some studies. Low-dose atropine causes a slight increase in pupil size, which allows more light to enter the eye. For most children on concentrations of 0.05% or lower, this effect is minimal and does not interfere with daily activities. Sunglasses or photochromic lenses can help on bright days if needed.
Some children experience mild difficulty with close-up focusing, particularly at higher concentrations. At the 0.01% to 0.05% range, poor near visual acuity has been reported in only about 2 to 3 percent of children. Reading and schoolwork are rarely affected. If near-vision concerns arise, progressive addition lenses or slight prescription adjustments can address the issue.
A small percentage of children may develop allergic conjunctivitis in response to the drops, causing redness, itching, or discomfort. This side effect is uncommon and resolves after discontinuation. If an allergic response occurs, we work with the family to explore alternative myopia control strategies.
Low-dose atropine has been studied in clinical trials lasting up to five years, and no significant long-term safety concerns have been identified. The drops do not cause permanent changes to the pupil, focusing ability, or overall eye health. A meta-analysis of multiple trials found that the minor differences in adverse events between atropine and placebo groups lacked clinical significance. Ongoing monitoring throughout treatment ensures any unexpected changes are caught early.
Frequently Asked Questions
Atropine therapy is most commonly initiated in children between the ages of 4 and 12, when myopia tends to progress most rapidly. Clinical trials have enrolled children as young as 3 years old. Starting treatment earlier in the progression curve generally provides the greatest cumulative benefit in reducing the final degree of myopia.
Treatment typically continues for at least two to three years, and in many cases longer. Because myopia tends to progress throughout childhood and into the late teenage years, many children benefit from sustained treatment until their prescription stabilizes. We reassess the treatment plan regularly and discuss the optimal timeline with each family based on the child's progression pattern.
Yes. Combining low-dose atropine with optical treatments such as orthokeratology lenses or multifocal soft contact lenses is an increasingly common approach, particularly for children with rapidly progressing myopia. Research suggests that combination therapy may provide greater myopia control than any single treatment alone.
Discontinuing atropine can lead to a rebound effect, where myopia progresses more quickly for a period after stopping the drops. The ATOM2 trial found that the rebound tends to be more pronounced with higher concentrations, with 68 percent of children on 0.5% atropine needing to restart treatment compared to only 24 percent of those on 0.01%. To minimize this risk, we typically taper the dose gradually rather than stopping abruptly.
As of early 2026, low-dose atropine does not have FDA approval for myopia control in the United States. It is prescribed off-label by eye care professionals based on the substantial body of clinical evidence supporting its use. In June 2025, the European Commission approved a 0.01% atropine formulation marketed as Ryjunea, making it the first approved pharmaceutical treatment for myopia progression in EU countries.
Because low-dose atropine for myopia is not yet FDA-approved in the US, insurance coverage varies. The drops are typically prepared by compounding pharmacies, and the monthly cost generally ranges from $30 to $75 depending on the pharmacy, concentration, and geographic region. The cost of monitoring visits, which typically include axial length measurements, should also be factored into the overall investment.
What our Patients say
4.8
Reviews
(3747)